skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Atypical antipsychotics to treat the neuropsychiatric symptoms of dementia

(1973) Views  (506) Full article downloads

Authors: Philip E Lee, Sudeep S Gill, Paula Rochon

Published Date February 2006 Volume 2006:2(4) Pages 521 - 529
DOI: http://dx.doi.org/10.2147/NDT.S

Philip E Lee1,3, Sudeep S Gill2,3, Paula Rochon3,4

1Division of Geriatric Medicine, University of British Columbia, BC, Canada; 2Department of Medicine, Queen’s University, Kingston, ON, Canada; 3Institute for Clinical Evaluative Sciences (ICES), Toronto, ON, Canada; 4Kunin-Lunenfeld Applied Research Unit, Toronto, ON, Canada

Abstract: Neuropsychiatric symptoms are common in older adults with dementia and can be associated with a rapid decline in cognitive and functional status. This article reviews the current literature supporting the use of atypical antipsychotic medications in this population. Among the currently available atypical antipsychotics, risperidone and olanzapine have been the most  widely studied in double-blind, randomized, placebo-controlled clinical trials. Despite the common use of other atypical antipsychotic medications, their efficacy and safety in older adults with dementia has not been as extensively studied. Some controversy surrounds the use of atypical antipsychotic agents in older adults with the suggestion that they may increase the incidence of stroke or even death. Despite the potential for increased risk of harm from the use of these medications, atypical antipsychotics are often effective in treating troublesome neuropsychiatric symptoms refractory to other treatments. Whenever possible, these atypical antipsychotic drug treatments should be combined with non-pharmacological treatments to limit the need and dose of antipsychotic drugs and constant monitoring for potential harms should be maintained. The choice of which atypical antipsychotic agent can be guided by the nature and severity of the target symptom and the medication least likely to cause harm to the patient.

Keywords: atypical antipsychotics, dementia, risperidone, olanzapine








Readers of this article also read:

Treatment of Alzheimer's disease across the spectrum of severity
Management of the behavioral and psychological symptoms of dementia
A neuropsychiatric review of pediatric obsessive-compulsive disorder: etiology and efficacious treatments
Atomoxetine: a novel treatment for child and adult ADHD
New agents in the treatment of premature ejaculation
The biopsychosocial effects of restless legs syndrome (RLS)
Hypoglycemia associated with insulin hypersecretion following the addition of olanzapine to conventional antipsychotics
Optimal management of Alzheimer’s disease patients: Clinical guidelines and family advice
Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761®. Findings from a randomized controlled trial
Clinical features and multidisciplinary approaches to dementia care